Radioactive Iodine Activities for Postsurgical Thyroid Ablation: The Lower the Better

Pacini, Furio

doi:10.1159/000346154

Cited by 2 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to discuss the study of Castagna et al [25], which assessed the effectiveness of 1. [26]. Although not statistically different in the two groups, the rates of persistent and recurrent disease and even death are concerning.…”

Section: Introductionmentioning

confidence: 77%

See 1 more Smart Citation

Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option

Clerc

Verburg

Avram

et al. 2017

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 77%

“…To simply raise as principle Bthe lower the better [ 26], makes little sense. In radiation oncology the proposition that a lesser radiation therapy dose is better would be unacceptable, and the same applies for chemotherapy treatment.…”

Section: Does Adjuvant or Therapeutic Rai Administration Improve Clinmentioning

confidence: 99%

Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option

Clerc

Verburg

Avram

et al. 2017

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…Using thyrotropin alfa for thyroid ablation before RAI administration is becoming the standard of care in many countries in preference to thyroid hormone withdrawal [ 14 , 15 ]. This is based on data showing diagnostic and therapeutic equivalence between the two thyroid ablation techniques, but thyrotropin alfa is associated with fewer adverse events and no deterioration in quality of life caused by hypothyroid symptoms [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Long-Term Safety and Effectiveness of Thyrotropin Alfa in Japanese Patients: A Post-Marketing Surveillance Study

2021

View full text Add to dashboard Cite

Introduction Real-world evidence of the safety and effectiveness of recombinant human thyroid-stimulating hormone (rhTSH; thyrotropin alfa) in Japanese patients is lacking. Methods This was a post-marketing surveillance study that included all Japanese patients who received thyrotropin alfa, either as a supporting diagnostic from January 2009 to December 2016, or as adjunctive treatment for ablation from May 2012 to October 2018. Information was collected on patient demographics, thyroid cancer characteristics, adverse drug reactions (ADRs), scintigraphy, serum thyroglobulin (Tg) testing, and hypothyroidism symptoms. Results A total of 9268 patients were included in the safety analysis and 9031 in the effectiveness analysis. In the safety analysis set, 3444 patients received thyrotropin alfa as a diagnostic and 5822 received it as treatment. ADRs occurred in 7.1% ( n = 660) of patients, including 9.4% ( n = 324) of patients who received thyrotropin alfa as a diagnostic and 5.8% ( n = 336) of patients who received it as treatment. Nausea was the most common ADR (4.0% of overall safety population). Among patients who received thyrotropin alfa as a diagnostic ( n = 1835), the Tg test was positive in 53.6% after the second dose. The scintigram was rated as “readable” in 3023 of the 3054 patients included in this analysis (99.0%). Of the 765 patients who were included in the assessment of response to ablation at 6 months to 1 year after the procedure, 621 (81.2%) were considered to have had “treatment success”. There were no significant differences in the proportions of patients who had hypothyroidism symptoms before the first and after the second dose of thyrotropin alfa. Conclusion In this large post-marketing surveillance study, thyrotropin alfa was well tolerated and showed effectiveness that was comparable to that observed in randomised, controlled trials.

show abstract

Radioactive Iodine Activities for Postsurgical Thyroid Ablation: The Lower the Better

Cited by 2 publications

References 16 publications

Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option

Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option

Long-Term Safety and Effectiveness of Thyrotropin Alfa in Japanese Patients: A Post-Marketing Surveillance Study

Contact Info

Product

Resources

About